Large prostate gland size is not a contraindication to low-dose-rate brachytherapy for prostate adenocarcinoma

In men with large prostates, the PSI provides biochemical control and temporal changes in genitourinary toxicity that are comparable with men having smaller glands. Accurate dose optimization and delivery of PSI provides the best clinical outcomes regardless of gland size.